Glycine N-methyltransferase enhancer, its preparation method and use
Nicotinohydrazide derivatives enhance GNMT expression in cancer cells, addressing the limitations of current HCC treatments by effectively inhibiting cell proliferation and offering a promising therapeutic approach for HCC.
Patent Information
- Application Number
- JP2022580223
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2020-12-25
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2040-12-25
AI Technical Summary
Current treatments for hepatocellular carcinoma (HCC) are limited, with existing drugs showing side effects and rapid drug resistance, and there is a need for new therapeutic strategies to enhance glycine N-methyltransferase (GNMT) expression to improve treatment efficacy.
Development of nicotinohydrazide derivatives and their stereoisomers or pharmaceutically acceptable salts, which are synthesized to enhance GNMT expression in cancer cells, including a method involving the reaction of ethyl nicotinate with hydrazine hydrate and condensation with acetylpyridine to form compounds like K117, enhancing GNMT promoter activity.
The nicotinohydrazide derivatives effectively induce GNMT expression, inhibiting cancer cell proliferation both in vitro and in vivo, providing a potential treatment for HCC with reduced toxicity and improved efficacy compared to existing drugs.
Smart Images

Figure 0007584163000013 
Figure 0007584163000014 
Figure 0007584163000015
Abstract
Description
[Technical field]
[0001] The present invention relates to a pharmaceutical composition for inhibiting cancer cells, in particular, to a pharmaceutical composition for inhibiting cancer cells by enhancing the expression of glycine N-methyltransferase (GNMT). [Background technology]
[0002] Hepatocellular carcinoma (HCC) is a global health burden with increasing incidence. Liver cancer is the fifth most common cancer and the third leading cause of cancer deaths worldwide. Due to late diagnosis, few treatment options, and high recurrence rates, the incidence of HCC is still nearly as high as its mortality rate. There are not many treatment options for HCC. Currently, the drugs approved by the Food and Drug Administration (FDA) for the treatment of HCC are sorafenib and regorefenib. These drugs are effective for only some people, but they have side effects and patients quickly develop drug resistance. Thus, there is a high unmet need for HCC. The development of new drugs for HCC has been very slow, and many compounds have failed in clinical trials. There is an urgent need to develop preventive drugs, new treatments, or drug combination strategies to improve patient survival and help control the disease.
[0003] GNMT is a tumor suppressor gene (TSG) for HCC. GNMT comprises 1–3% of the cytoplasmic protein in normal mammalian liver, but GNMT is downregulated in more than 75% of HCC patients. GNMT is one of the key enzymes in the one-carbon metabolic pathway. It affects genetic stability by regulating the ratio of S-adenosylmethionine to S-adenosylhomocystine and functions as the major folate-binding protein in hepatocytes. Furthermore, previous studies have suggested that GNMT is an example of a moonlighting protein. GNMT can switch its function from a metabolic enzyme to a 4S polycyclic aromatic hydrocarbon (PAH)-binding protein based on its phosphorylation status, which changes the composition of its subunits. By changing the cellular localization of GNMT from the cytoplasm to the nucleus, GNMT can act as a transcriptional cofactor and regulate the expression of detoxification (and / or other target) genes.
[0004] Previously, in the GNMT- / - mouse model, it was discovered that both male and female GNMT- / - mice developed chronic hepatitis at 4–11 weeks of age. These GNMT- / - mice were followed up until 24 months of age, and the results showed that all of the female GNMT- / - mice and half of the male GNMT- / - mice developed HCC. In contrast, re-expression of GNMT inhibits cell proliferation of cancer cells. Most importantly, transgenic mice overexpressing GNMT were protected against aflatoxin (AFB1)-induced carcinogenesis and liver cancer progression. More importantly, it was demonstrated that GNMT suppressed the proliferation of Huh7 cells and sensitized them to rapamycin treatment both in vitro and in vivo. Recently, it was further demonstrated that overexpression of GNMT sensitized Huh7 cells not only to rapamycin but also to sorafenib treatment both in vitro and in vivo. Therefore, considering the strong association between GNMT deficiency and liver damage, and the protective role of GNMT against hepatocarcinogenesis, accurate identification of small molecule compounds that can enhance GNMT expression has important implications for the treatment of HCC.
[0005] Preliminary results showed that the small molecule K78 has an IC50 value of 2.5 μM in Huh7 cells, making it a promising lead for the treatment of HCC. In collaboration with the medicinal chemistry team, a comprehensive structure-activity relationship (SAR) study on K78 was conducted. In this invention, K series compounds (K78 derivatives) are synthesized to identify the ability of K78 and its derivatives to induce GNMT promoter reporter activity.
[0006] The applicant has developed the present invention to overcome the shortcomings of the prior art. Summary of the Invention [Problem to be solved by the invention]
[0007] The main objective of the present invention is to provide a novel GNMT enhancer for treating cancer via increasing GNMT expression in cancer cells. [Means for solving the problem]
[0008] Accordingly, the present invention provides a nicotinohydrazide derivative, a stereoisomer or a pharmacologically acceptable salt thereof, the nicotinohydrazide derivative having the structure of formula (I): [ka] Each of X, Y and Z is either N or CH, at least one of X, Y and Z is CH, at least one of X, Y and Z is N, and R is OH or NH 2 Either:
[0009] In order to synthesize preferred embodiments of compounds having formula (I), the present invention provides a method for preparing a nicotinohydrazide derivative, the method comprising the steps of reacting ethyl nicotinate with hydrazine hydrate to form a carbohydrazide, and carrying out a condensation reaction of the carbohydrazide with acetylpyridine to form N'-(1-(pyridin-2-yl)ethylidene)-2-carbohydrazide (K117) having the following structure: [ka]
[0010] The present invention further provides a pharmaceutical composition comprising an effective amount of a nicotinohydrazide derivative, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof, wherein the nicotinohydrazide derivative has the structure of formula (I).
[0011] In a further aspect, the present invention provides the use of the above-mentioned nicotinohydrazide derivative, its stereoisomer or its pharma- ceutically acceptable salt for preparing a medicament for the treatment of cancer disease. The nicotinohydrazide derivative has the structure of formula (I), which is [ka] It is expressed as where X is either N or CH, Y and Z are either CH, and R is either OH or NH. 2 Either: [Brief description of the drawings]
[0012] [Figure 1] 1 is a flow chart for the synthesis of preferred embodiments of the nicotinohydrazide derivatives of the present invention. [Figure 2A] The structure of K78 is shown. [Figure 2B] The effect of K78 on the expression of GNMT is shown. [Figure 2C] The effect of K78 on the expression of GNMT is shown. [Figure 2D] The effect of K78 on the expression of GNMT is shown. [Figure 3A] FIG. 1 shows the effect of K78 on inhibiting the proliferation of liver cancer cells in vitro and in vivo. [Figure 3B] FIG. 1 shows the effect of K78 on inhibiting the proliferation of liver cancer cells in vitro and in vivo. [Figure 3C] FIG. 1 shows the effect of K78 on inhibiting the proliferation of liver cancer cells in vitro and in vivo. [Figure 3D]FIG. 1 shows the effect of K78 on inhibiting the proliferation of liver cancer cells in vitro and in vivo. [Figure 4A] The structure of K102 is shown. [Figure 4B] 1 shows the effects of compounds K117 and K102 on GNMT expression. [Figure 4C] 1 shows the effects of compounds K117 and K102 on GNMT expression. [Figure 4D] 1 shows the effects of compounds K117 and K102 on GNMT expression. [Figure 5A] 1 shows the effect of K117 on inhibiting the proliferation of hepatocarcinoma cells in vitro and in vivo. [Figure 5B] 1 shows the effect of K117 on inhibiting the proliferation of hepatocarcinoma cells in vitro and in vivo. [Figure 5C] 1 shows the effect of K117 on inhibiting the proliferation of hepatocarcinoma cells in vitro and in vivo. [Figure 5D] 1 shows the effect of K117 on inhibiting the proliferation of hepatocarcinoma cells in vitro and in vivo. [Figure 5E] 1 shows the effect of K117 on inhibiting the proliferation of hepatocarcinoma cells in vitro and in vivo. [Figure 5F] 1 shows the effect of K117 on inhibiting the proliferation of hepatocarcinoma cells in vitro and in vivo. [Figure 6A] The structure of K90 is shown. [Figure 6B] 1 shows the effect of GNMT-inducing compounds on Myc expression. [Figure 6C] 1 shows the effect of GNMT-inducing compounds on Myc expression. [Figure 6D] 1 shows the effect of GNMT-inducing compounds on Myc expression. [Figure 6E] 1 shows the effect of GNMT-inducing compounds on Myc expression. [Figure 6F] 1 shows the effect of GNMT-inducing compounds on Myc expression. [Figure 6G] 1 shows the effect of GNMT-inducing compounds on Myc expression. [Figure 6H]1 shows the effect of GNMT-inducing compounds on Myc expression. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0013] According to one aspect of the present invention, there is provided a nicotinohydrazide derivative, a stereoisomer or a pharma- ceutically acceptable salt thereof. In one preferred embodiment, the nicotinohydrazide derivative has the structure of formula (I): [ka] wherein each of X, Y and Z is either N or CH, at least one of X, Y and Z is CH, at least one of X, Y and Z is N, and R is OH or NH 2 Either:
[0014] The term "nicotinohydrazide derivative" as used herein refers to a nicotinohydrazide derivative, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof.
[0015] In another aspect of the present invention, a pharmaceutical composition is provided that comprises a nicotinohydrazide derivative, its stereoisomer, or its pharmaceutically acceptable salt. The definition of a nicotinohydrazide derivative, its stereoisomer, or its pharmaceutically acceptable salt is as above. Preferably, the pharmaceutical composition further comprises at least one of a pharmaceutically acceptable carrier and excipient.
[0016] In a further aspect of the present invention, there is provided a method for preparing a preferred embodiment of a nicotinohydrazide derivative, comprising reacting ethyl nicotinate with hydrazine hydrate to form a carbohydrazide, and carrying out a condensation reaction of the carbohydrazide with acetylpyridine to form N'-(1-(pyridin-2-yl)ethylidene)-2-carbohydrazide (K117) having the following structure: [ka]
[0017] According to the present invention, the ethyl nicotinate is ethyl 2-aminonicotinate, the carbohydrazide is 2-carbohydrazide, and the acetylpyridine is 2-acetylpyridine.
[0018] In a further aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a nicotinohydrazide derivative, its stereoisomer or its pharma- ceutically acceptable salt. The nicotinohydrazide derivative has the structure of formula (I) above. Preferably, the pharmaceutical composition further comprises at least one of a pharma- ceutically acceptable carrier and excipient.
[0019] In a further aspect, the present invention provides the use of the above nicotinohydrazide derivatives, their stereoisomers and pharma- ceutically acceptable salts for the preparation of a medicament for the treatment of cancer disease, said nicotinohydrazide derivatives having the structure of formula (I): [ka] where X is either N or CH, Y and Z are either CH, and R is either OH or NH. 2 Either:
[0020] As used herein, the term "cancer" refers to a cellular disorder characterized by uncontrolled or unregulated cell proliferation, reduced cell differentiation, inappropriate ability to invade surrounding tissues, and / or ability to establish new growth at ectopic sites. The term "cancer" includes, but is not limited to, solid tumors and blood-borne tumors. The term "cancer" includes diseases of the skin, tissues, organs, bone, cartilage, blood, and blood vessels. The term "cancer" further includes primary and metastatic cancers. Non-limiting examples of cancer in the present invention include liver cancer, prostate cancer, and pancreatic cancer. Preferably, the liver cancer is hepatocellular carcinoma.
[0021] The pharmaceutical composition of the present invention is used to treat cancer through enhancing GNMT expression in cancer cells. EXAMPLES
[0022] 1. Synthesis of nicotinohydrazide derivatives Please refer to Figure 1, which shows a flow chart for the synthesis of a preferred embodiment (K117) of the nicotinohydrazide derivative of the present invention. Ethyl 2-aminonicotinate was reacted with hydrazine hydrate to obtain 2-carbohydrazide. As shown in Figure 1, 2-carbohydrazide was condensed with 2-acetylpyridine to obtain N'-(1-(pyridin-2-yl)ethylidene)-2-carbohydrazide (K117).
[0023] In another embodiment, other K series compounds are synthesized using different ethyl nicotinates. Ethyl 2-hydroxynicotinate, ethyl 3-aminoisonicotinate, and ethyl 3-aminopyrazine-2-carboxylate are each reacted with hydrazine hydrate to obtain the respective 2-carbohydrazides. Each of the 2-carbohydrazides is then condensed with 2-acetylpyridine to obtain other compounds having the structure of formula (I). The structures of these compounds are represented as follows: [ka] K118 X=N, Y=Z=CH, R=OH K120 X=N, X=Z=CH, R=NH 2 K121 X=Z=N, Y=CH, R=NH 2
[0024] 2. Cell culture and reagents Human liver cancer cell lines (Huh7 and HepG2), human pancreatic cancer cell line (PANC1) and prostate cancer cell line (PC3) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (HyClone, Logan, UT, USA), L-glutamine (2 mM), streptomycin (100 μg / mL), penicillin (100 U / mL) and non-essential amino acids (0.1 mM). Human pancreatic cancer cell line BxPC3 was cultured in Roswell Park Memorial Institute (RPMI) 1640 medium containing the same supplements as DMEM. All cell lines were maintained at 37 °C in a humidified CO2 incubator. H7GPL stable cells established by the lentiviral system were grown in DMEM supplemented with 1 μg / mL puromycin. Sorafenib was purchased from Sigma-Aldrich (St. Louis, MO, USA).
[0025] 3. GNMT induction ability analysis -1812 / +14 GNMT promoter-luciferase reporter cell line H7GPL was constructed. In the primary analysis, H7GPL cells seeded in 96-well plates were treated with 10 μM of individual drugs for 24 h and then lysed for luciferase activity assay using a luciferase assay system (Promega, Madison, WI, USA). Secondary analysis was then performed with different doses of compounds. The same confirmed hits were used for cytotoxicity using alamarBlueR reagent (AbD Serotec, Oxford, UK). Cytotoxicity was measured according to the manufacturer's recommendations. Hot data were used for further studies.
[0026] 4. Cell viability and colony formation analysis Huh7, HepG2, PANC1, PC3 and BxPC3 cells were seeded in 96-well plates for 24 h and exposed to various concentrations of drugs. AlamarBlue® was added to the cells and incubated for an additional 4 h to evaluate the cytotoxic effect of the test drugs. Blank wells (without cells) containing the same amount of test substance were used for background subtraction and the relative number of viable cells was expressed as a percentage of the mean of the relative solvent control. Cell viability was assessed using the AlamarBlue® assay (AbD Serotec, Oxford, UK) according to the manufacturer's instructions.
[0027] 5. Immunoblotting Protease inhibitor cocktail (Roche Molecular Biochemicals) and phosphatase inhibitors (10 mM Na 3 VO 4 Cells or xenograft tumors were harvested for lysate preparation using RIPA buffer containing 1 mM NaF, 1 mM NaPPi. Protein concentrations were quantified by Bio-Rad protein assay (Bio-Rad) and immunoblotting was performed as previously described ( Yen et al., 2012 ). Anti-MYC (D84C12, Cell Signaling Technology), anti-GNMT (YMAC-Bioteck) and anti-β-actin (AC-15, Sigma-Aldrich) antibodies were used as described in the manufacturer's instructions.
[0028] 6. Quantitative real-time PCR (qRT-PCR) RNA was isolated using Trizol reagent (Life Technologies) according to the manufacturer's protocol. Cellular RNA was reverse transcribed into complementary DNA using the SuperScript II RNase H-reverse transcriptase kit (Life Technologies). PCR reactions were performed using the Super Script II reverse transcriptase kit (Invitrogen Inc., Carlsbad, CA, USA) on an Applied Biosystems Step-One-plus real-time PCR system (Applied Biosystems, Foster City, CA, USA). TATA-box binding protein (TBP) mRNA levels were used as an internal control. The primer pairs used for qRT-PCR were as follows: TBP forward: SEQ ID NO: 1, Reverse: SEQ ID NO:2, MYC forward: SEQ ID NO:3, Reverse: SEQ ID NO:4, p21 forward: SEQ ID NO:5, Reverse: SEQ ID NO:6, p27 forward: SEQ ID NO:7, Reverse: SEQ ID NO:8, GNMT forward: SEQ ID NO:9, and Reverse: SEQ ID NO:10.
[0029] 7. Plasmids and transfection Plasmids for lentivirus production (pCMV-ΔR8.91 and pMD.G), shRNA for MYC (MYC-lentiviral shRNA, SEQ ID NO: 11) and control plasmid for RNA interference (pLKO.1-shLacZ) were obtained from the National RNAi Core Facility (Academia Sinica, Taipei, Taiwan). Vector control plasmids and pcDNA-MYC plasmid for overexpression experiments were provided by Dr. Shih-Ping Liu (China Medical University, Taichung, Taiwan). Renilla luciferase control reporter vector (Promega, Madison, WI, USA) was used to normalize transfection efficiency. Plasmid DNA was transfected using TurboFect Reagent (Fermentas, Hannover, MD) and Lipofectamine 3000 (Life Technologies, Mulgrave, Australia) according to the manufacturer's recommendations. Plasmid DNA was transfected using TurboFect™ reagent and Lipofectamine 3000 according to the manufacturer's recommendations.
[0030] 8. Xenograft analysis All animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee of Kaohsiung Medical University and were performed in accordance with the relevant guidelines. Huh7 cells (1 x 10 6 ) was injected subcutaneously. Once palpable tumors were detected, mice were randomized into groups and treated with 300mpk, 100mpk, or 25mpk of LKY4606D or KYT5397 and drug vehicle orally administered daily for 28 days. For K117, doses of 10mpk and 25mpk were used. For sorafenib, a dose of 25mpk was used. Tumor growth was monitored (daily or three times a week) by measuring the length (L) and width (W) of the tumor using calipers. Tumor volume (TV) was calculated according to the formula: Volume = (L × W 2 ) / 2. All drugs were dissolved in 0.5% carboxymethylcellulose sodium salt.
[0031] 9, Statistical analysis Statistical analysis was performed using MS excel and Graph Pad Prism 5.0 software. For comparison of various groups, P values were determined by two-tailed Student's t test, and P < 0.05 was considered statistically significant.
[0032] result 1. Identification of GNMT inducers Preliminary studies indicated that a naphthohydrazide derivative, K78, whose structure is shown in Figure 2A, is a potent lead for HCC treatment. As shown in Figure 2B, K78 showed a dose-dependent induction of luciferase activity and was selected as a potential candidate for an inducer of reporter gene expression. To confirm whether K78 enhances endogenous GNMT expression, we examined GNMT mRNA and protein levels in Huh7 cells. In Figures 2C and 2D, K78 upregulated endogenous GNMT expression at the mRNA level (Figure 2C) and protein level (Figure 2D) in Huh7 cells.
[0033] 2. Anti-HCC effects of K78 in vitro and in vivo To determine the therapeutic potential of K78 for HCC, we first evaluated the inhibitory effect of K78 on the proliferation of Huh7 cells. K78 dose-dependently suppressed the proliferation of Huh7 cells after 72 hours of treatment (Figure 3A). Subsequently, after 24, 48, 72 and 96 hours of exposure to K78, the proliferation of Huh7 cells was significantly inhibited in a time-dependent manner (Figure 3B). Next, we conducted a study on a xenogeneic model using Huh7 cells. Tumor-bearing nude mice were orally treated with vehicle K78 25mpk, K78 100mpk and K78 300mpk. Sorafenib was chosen as a comparative control because it is an FDA-approved drug for HCC. There was no evidence of toxicity on body weight in all groups (Figure 3C). As shown in Figure 3D, K78 inhibited tumor growth in this model compared to the vehicle control group. However, sorafenib had the most significant difference. Taken together, these results provide strong evidence for the anti-HCC potential of K78 using in vitro and in vivo models.
[0034] By performing structure-activity relationship (SAR) studies, we identified more potent HCC inhibitors with the ability to enhance GNMT expression. K117 and K102 (K78 derivatives) are more effective than K78 in inducing GNMT expression. The structure of K102 is shown in Figure 4A. Furthermore, K117 and K102 induced GNMT promoter activity in a dose-dependent manner (Figure 4B). Then, the most potent inducer, K117, was selected for further study to induce GNMT mRNA and protein expression in Huh7 cells (Figure 4C and Figure 4D).
[0035] By performing structure-activity relationship (SAR) studies, K-series compounds (GNMT inducers) were synthesized with different ethyl nicotinate, as shown in Table 1. Table 1 shows the GNMT induction ability of K-series compounds.
[0036] [Table 1]
[0037] 3. K117 inhibits hepatocellular carcinoma cells in vitro and in vivo Next, we analyzed the effect of K117 on cell proliferation of various hepatoma cell lines (including Huh7, Hep3B and HepG2). The results showed that K117 dose-dependently inhibited the proliferation of all hepatoma cells tested (Figure 5A). Furthermore, K117 dose-dependently reduced the colony formation of Huh7 and HepG2 cells (Figures 5B and 5C). To further evaluate the antitumor effect of K117 in vivo, Huh7 cells were subcutaneously injected into nude mice as described above. These mice were then randomly divided into groups and treated with vehicle, K117 25mpk, K117 10mpk and sorafenib 25mpk (as a comparative control).
[0038] As shown in Figure 5D, a significant tumor growth reduction was observed in the K117-treated group when compared to the control group. Moreover, a low dose of K117, 10 mpk, showed the same effect as sorafenib, 25 mpk. Furthermore, K117 treatment did not cause any severe adverse events, monitored by animal survival, body weight, and liver function tests, with no significant difference between all groups (Figure 5E and 5F). Overall, these results provide strong evidence of the tumor growth inhibitory activity and tolerance of K117 in vitro and in vivo.
[0039] 4. GNMT functions as a tumor susceptibility gene (TSG) in prostate and pancreatic cancer It has been reported that GNMT expression is abundant in normal prostate and benign prostatic hyperplasia tissues but is decreased in 82.2% of prostate cancer tissues, suggesting that GNMT is a tumor susceptibility gene for prostate cancer.
[0040] It has been found that hypermethylation is utilized for gene silencing in many cancers, including pancreatic cancer. In such conditions, downregulation of GNMT may help to enable the methyl donor SAM to carry out gene silencing. Previously, GNMT was found to be significantly downregulated in pancreatic cancer, and secondary tumors of pancreatic cancer usually target the liver. In this respect, it is similar to HCC that GNMT may be a TSG in pancreatic cancer, and reactivation of this downregulated TSG in pancreatic cancer would be a therapeutic plan. Table 2 shows the IC50 (μM) of pancreatic and prostate cancer cell lines. This indicates that induction of GNMT inhibits cancer cell proliferation.
[0041] [Table 2]
[0042] 5. Mechanism of K78 series GNMT inducers in HCC Next, the mechanism by which K78 enhances GNMT expression and inhibits the proliferation of liver cancer cells was investigated in the present invention. GNMT inducer drug, i.e., 1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranoside (PGG), is known to enhance GNMT expression via MYC downregulation in the pathogenesis of liver cancer. Therefore, to determine whether K78 series compounds also exert their effects through MYC inhibition in HCC, the effect of treatment of K78 series compounds (K78, K90 and K102) on MYC mRNA expression in Huh7 cells was examined in the present invention. The structure of K90 is shown in Figure 6A. As shown in Figure 6B, all K78 series compounds (K78, K90 and K102) inhibit MYC mRNA expression in Huh7 cells. Furthermore, it was shown that K117 suppressed c-Myc mRNA expression in a dose-dependent manner (Figure 6C). Furthermore, we evaluated the effect of K117 on MYC function by analyzing the expression of MYC target genes after K117 treatment. Consistent with MYC inhibition, K117 treatment increased p21 and p27 mRNA expression in Huh7 cells (Figure 6D). Consistent with the in vitro results, MYC protein expression was reduced in Huh7 xenograft tumors in mice treated with K117 (Figure 6E). These results indicate that K78 series compounds are MYC inhibitors that suppress MYC expression in HCC cells. PGG has been shown to inhibit MYC gene expression and promote MYC protein degradation through a mechanism independent of the proteasome, similar to calpain. To investigate the action of this same mechanism in K78 series compounds, we investigated whether ectopic expression of MYC rescues K117-induced MYC mRNA and protein suppression in Huh7 cells. Interestingly, ectopic expression of MYC could rescue K117-induced MYC mRNA and protein repression in Huh7 cells (Figure 6F and Figure 6G). Furthermore, induction results showed that overexpression of MYC restored K117-induced GNMT promoter activity in H7GPL-1 cells (Figure 6H). Taken together, K78 series compounds repressed MYC transcription and enhanced GNMT expression.
[0043] The present invention may be modified in any way by a person skilled in the art without departing from the scope of the appended claims.
Claims
1. A nicotinohydrazide derivative having the structure of formula (I), a stereoisomer thereof, or a pharmacologically acceptable salt thereof, 【Chemistry 1】 The nicotinohydrazide derivative, its stereoisomer or pharmacologically acceptable salt, characterized in that X, Y and Z are each either N or CH, at least one of X, Y and Z is CH, at least one of X, Y and Z is N, and R is NH2.
2. A method for preparing a nicotinohydrazide derivative comprising the steps of: reacting ethyl 2-aminonicotinate with hydrazine hydrate to form 2-carbohydrazide; and performing a condensation reaction of the 2-carbohydrazide with 2-acetylpyridine to form N'-(1-(pyridin-2-yl)ethylidene)-2-carbohydrazide having the following structure: 【Chemistry 2】
3. A pharmaceutical composition comprising an effective amount of the nicotinohydrazide derivative, its stereoisomer or a pharmacologically acceptable salt thereof according to claim 1.
4. Use of a nicotinohydrazide derivative having the structure of formula (I), its stereoisomer or pharmacologically acceptable salt in the preparation of a medicament for treating a cancer disease, comprising: 【Chemistry 3】 The above use, wherein X is either N or CH, each of Y and Z is CH, and R is NH2.
5. The use according to claim 4, characterized in that the cancer disease is selected from the group consisting of liver cancer, prostate cancer and pancreatic cancer.
6. The use according to claim 5, characterized in that the liver cancer is hepatocellular carcinoma.
7. The use according to claim 4, wherein the nicotinohydrazide derivative, its stereoisomer or pharmacologically acceptable salt has an effect of enhancing glycine N-methyltransferase (GNMT).
Citation Information
Patent Citations
STAT3 small-molecule inhibitor and its application
CN103880707A
Compounds for targeting cancer stem cells
WO2018017589A1
